Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK559649PMID: 32697454
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 19171-19-8
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the use of pomalidomide during breastfeeding. The manufacturer recommends that breastfeeding be discontinued during pomalidomide therapy
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Pomalidomide
CAS Registry Number
19171-19-8
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Distribution of pomalidomide into semen of healthy male subjects after multiple doses.[Clin Pharmacol. 2018]Distribution of pomalidomide into semen of healthy male subjects after multiple doses.Li Y, Wang X, Liu L, Reyes J, Palmisano M, Zhou S. Clin Pharmacol. 2018; 10:53-62. Epub 2018 May 7.
- 2,4,6-Triamino-1,3,5-triazine-1H-isoindole-1,3(2H)-dione (1/3).[Acta Crystallogr C. 2007]2,4,6-Triamino-1,3,5-triazine-1H-isoindole-1,3(2H)-dione (1/3).Perpétuo GJ, Janczak J. Acta Crystallogr C. 2007 May; 63(Pt 5):o301-2. Epub 2007 Apr 21.
- Review Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma.[Drugs. 2017]Review Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma.Hoy SM. Drugs. 2017 Nov; 77(17):1897-1908.
- Review Pomalidomide: a review of its use in patients with recurrent multiple myeloma.[Drugs. 2014]Review Pomalidomide: a review of its use in patients with recurrent multiple myeloma.Scott LJ. Drugs. 2014 Apr; 74(5):549-62.
- The Synthesis, Anticancer Activity, Structure-Activity Relationships and Molecular Modelling Studies of Novel Isoindole-1,3(2H)-dione Compounds Containing Different Functional Groups.[Anticancer Agents Med Chem. 2020]The Synthesis, Anticancer Activity, Structure-Activity Relationships and Molecular Modelling Studies of Novel Isoindole-1,3(2H)-dione Compounds Containing Different Functional Groups.Tan A, Kizilkaya S, Kelestemur U, Akdemir A, Kara Y. Anticancer Agents Med Chem. 2020; 20(11):1368-1378.
- Pomalidomide - Drugs and Lactation Database (LactMed®)Pomalidomide - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...